Search results
Results from the WOW.Com Content Network
Ivabradine did not significantly improve the secondary outcomes in patient groups, however did demonstrate a reduction in heart rate. When compared to the SHIFT study, a reduction in cardiovascular death or hospital admission was also demonstrated and hence should be considered when additional therapy is in question.
This article needs more reliable medical references for verification or relies too heavily on primary sources, specifically: Unsourced list of side effects, needs references. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed
Ivabradine is the most specific and selective I f inhibitor and the only member of this family that is now marketed for pharmacological treatment of chronic stable angina in patients with normal sinus rhythm who have a contraindication or intolerance to beta-blockers. Recent studies have also indicated that funny channel inhibition can be used ...
Here are links to possibly useful sources of information about Ivabradine. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC
Mayo Clinic Health System is a system of community-based medical facilities. It is owned by Mayo Clinic and was founded in 1992. The organization focuses on providing medical care in rural communities in Minnesota , Iowa , and Wisconsin .
The effects of self hypnosis on chronic pain are roughly comparable to those of progressive muscle relaxation. [ 44 ] A 2019 systematic review of 85 studies showed it to be significantly effective at reducing pain for people with high and medium levels of suggestibility, but of minimal effectiveness for people with low suggestibility.
A study into the effects of the benzodiazepine receptor antagonist, flumazenil, on benzodiazepine withdrawal symptoms persisting after withdrawal was carried out by Lader and Morton. Study subjects had been benzodiazepine-free for between one month and five years, but all reported persisting withdrawal effects to varying degrees.
Trodusquemine is an aminosterol (polyamine steroid conjugate) that inhibits protein tyrosine phosphatase 1B (PTP1B) activity. [1] The compound exhibits broad-spectrum antimicrobial activity [2] and numerous regenerative, neuroprotective, anti-atherosclerotic, antitumor, antiangiogenic, antiobesity, and anxiolytic properties. [3]